Beacon Investment Advisory Services’s Denali Therapeutics DNLI Stock Holding History

Beacon Investment Advisory Services’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,000	Closed	-$223K	–	302
2021 Q4	$223K	Hold	5,000	–	–	0.01%	289
2021 Q3	$252K	Hold	5,000	–	–	0.01%	267
2021 Q2	$392K	Hold	5,000	–	–	0.02%	233
2021 Q1	$286K	Hold	5,000	–	–	0.01%	257
2020 Q4	$419K	Buy	+5,000	New	+$302K	0.02%	200

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Beacon Investment Advisory Services's DNLI Position: Q1 2022 in Review

Beacon Investment Advisory Services sold out of Denali Therapeutics (DNLI) in Q1 2022, closing a stake of 5,000 shares — an estimated $223K sold.

Beacon Investment Advisory Services first reported a position in DNLI in Q4 2020 and held it in 5 quarters. The position peaked at $419K in Q4 2020. 190 funds tracked by Wall St. Rank hold DNLI as of Q1 2022.

Beacon Investment Advisory Services reported no remaining Denali Therapeutics position as of Q1 2022 after selling out during the quarter.
Beacon Investment Advisory Services sold 5,000 Denali Therapeutics shares in Q1 2022, an estimated $223K.
Beacon Investment Advisory Services first reported a position in Denali Therapeutics in Q4 2020 and held it in 5 quarters.
Beacon Investment Advisory Services's Denali Therapeutics position peaked at $419K in Q4 2020.
190 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2022.

Based on Beacon Investment Advisory Services's 13F filing for Q1 2022, filed 12 May 2022.